Mark Wolff

7.6k total citations · 2 hit papers
63 papers, 5.3k citations indexed

About

Mark Wolff is a scholar working on Epidemiology, Infectious Diseases and Microbiology. According to data from OpenAlex, Mark Wolff has authored 63 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Epidemiology, 17 papers in Infectious Diseases and 13 papers in Microbiology. Recurrent topics in Mark Wolff's work include Influenza Virus Research Studies (32 papers), Respiratory viral infections research (25 papers) and Pneumonia and Respiratory Infections (9 papers). Mark Wolff is often cited by papers focused on Influenza Virus Research Studies (32 papers), Respiratory viral infections research (25 papers) and Pneumonia and Respiratory Infections (9 papers). Mark Wolff collaborates with scholars based in United States, Madagascar and Italy. Mark Wolff's co-authors include Robert B. Belshe, John J. Treanor, Kenneth M. Zangwill, Paul M. Mendelman, Thomas Rowe, James D. Campbell, James C. King, David I. Bernstein, William C. Gruber and Ken Zangwill and has published in prestigious journals such as New England Journal of Medicine, JAMA and PEDIATRICS.

In The Last Decade

Mark Wolff

63 papers receiving 5.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children

1998 697 citations Robert B. Belshe, Paul M. Mendelman et al. New England Journal of Medicine profile →
Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine

2006 562 citations John J. Treanor, James D. Campbell et al. New England Journal of Medicine profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Mark Wolff	3.6k	1.6k	1.3k	789	640	63	5.3k
John J. Treanor	5.9k 1.6×	3.0k 1.9×	2.2k 1.7×	1.3k 1.6×	312 0.5×	126	8.2k
Amalia Magaret	4.4k 1.2×	1.6k 1.0×	899 0.7×	374 0.5×	979 1.5×	145	6.2k
Gaston De Serres	8.2k 2.3×	3.1k 2.0×	990 0.8×	639 0.8×	268 0.4×	299	10.5k
D. Scott Schmid	5.2k 1.4×	1.2k 0.8×	1.0k 0.8×	461 0.6×	1.2k 1.9×	148	6.8k
Hugues Charest	3.3k 0.9×	1.6k 1.0×	1.2k 0.9×	633 0.8×	718 1.1×	91	5.2k
Christine Johnston	2.5k 0.7×	912 0.6×	1.0k 0.8×	409 0.5×	518 0.8×	115	4.8k
David W. Kimberlin	5.8k 1.6×	2.6k 1.7×	638 0.5×	441 0.6×	382 0.6×	153	7.1k
Wendy A. Keitel	2.4k 0.7×	904 0.6×	669 0.5×	635 0.8×	95 0.1×	87	3.5k
Emanuele Montomoli	2.8k 0.8×	2.1k 1.3×	1.3k 1.0×	940 1.2×	161 0.3×	210	5.1k
Anne A. Gershon	8.5k 2.3×	1.2k 0.8×	788 0.6×	394 0.5×	2.2k 3.5×	219	9.8k

Countries citing papers authored by Mark Wolff

Since Specialization

Citations

This map shows the geographic impact of Mark Wolff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Wolff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Wolff more than expected).

Fields of papers citing papers by Mark Wolff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Wolff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Wolff. The network helps show where Mark Wolff may publish in the future.

Co-authorship network of co-authors of Mark Wolff

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Wolff. A scholar is included among the top collaborators of Mark Wolff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Wolff. Mark Wolff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brady, Rebecca C., Lisa A. Jackson, Sharon E. Frey, et al.. (2018). Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. Vaccine. 36(31). 4663–4671. 12 indexed citations

Kotloff, Karen L., Natasha Halasa, Christopher J Harrison, et al.. (2014). Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children. The Pediatric Infectious Disease Journal. 33(8). 865–871. 8 indexed citations

Frey, Sharon E., David I. Bernstein, Rebecca C. Brady, et al.. (2014). Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009–2010 seasonal trivalent influenza vaccinations. Vaccine. 33(1). 163–173. 4 indexed citations

Wolff, Mark, Arlene C. Seña, David H. Martin, et al.. (2012). Rapid Plasma Reagin Titer Variation in the 2 Weeks After Syphilis Therapy. Sexually Transmitted Diseases. 39(8). 645–647. 23 indexed citations

Chen, Wilbur H., Patricia Winokur, Kathryn M. Edwards, et al.. (2012). Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine. 30(28). 4240–4248. 17 indexed citations

Belshe, Robert B., Sharon E. Frey, Irene Graham, et al.. (2011). Safety and Immunogenicity of Influenza A H5 Subunit Vaccines: Effect of Vaccine Schedule and Antigenic Variant. The Journal of Infectious Diseases. 203(5). 666–673. 50 indexed citations

Frenck, Robert W., Robert B. Belshe, Rebecca C. Brady, et al.. (2011). Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine. 29(34). 5666–5674. 52 indexed citations

Hook, Edward W., Frieda Behets, Kathleen Van Damme, et al.. (2010). A Phase III Equivalence Trial of Azithromycin versus Benzathine Penicillin for Treatment of Early Syphilis. The Journal of Infectious Diseases. 201(11). 1729–1735. 81 indexed citations

Hill, Heather, et al.. (2008). Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine after Priming with an Antigenic Variant. The Journal of Infectious Diseases. 198(5). 635–641. 73 indexed citations

10.

Treanor, John J., James D. Campbell, Kenneth M. Zangwill, Thomas Rowe, & Mark Wolff. (2006). Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine. New England Journal of Medicine. 354(13). 1343–1351. 562 indexed citations breakdown →

11.

Treanor, John J., Gilbert M. Schiff, Robert B. Couch, et al.. (2006). Dose‐Related Safety and Immunogenicity of a Trivalent Baculovirus‐Expressed Influenza‐Virus Hemagglutinin Vaccine in Elderly Adults. The Journal of Infectious Diseases. 193(9). 1223–1228. 95 indexed citations

12.

Treanor, John J., Wendy A. Keitel, Robert B. Belshe, et al.. (2002). Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 20(7-8). 1099–1105. 53 indexed citations

13.

King, James C., Patricia Fast, Kenneth M. Zangwill, et al.. (2001). Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. The Pediatric Infectious Disease Journal. 20(12). 1124–1131. 67 indexed citations

14.

Treanor, John J., Bethanie Wilkinson, Jean Hu‐Primmer, et al.. (2001). Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine. 19(13-14). 1732–1737. 283 indexed citations

15.

McElrath, M. Juliana, Lawrence Corey, David C. Montefiori, et al.. (2000). A Phase II Study of Two HIV Type 1 Envelope Vaccines, Comparing Their Immunogenicity in Populations at Risk for Acquiring HIV Type 1 Infection. AIDS Research and Human Retroviruses. 16(9). 907–919. 45 indexed citations

16.

Belshe, Robert B., William C. Gruber, Paul M. Mendelman, et al.. (2000). Correlates of Immune Protection Induced by Live, Attenuated, Cold‐Adapted, Trivalent, Intranasal Influenza Virus Vaccine. The Journal of Infectious Diseases. 181(3). 1133–1137. 321 indexed citations

17.

Rennels, Margaret B., Janet A. Englund, David I. Bernstein, et al.. (2000). Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. The Pediatric Infectious Disease Journal. 19(5). 417–423. 30 indexed citations

18.

Wolff, Mark, Lawrence H. Moulton, Wendy Newcomer, Raymond Reid, & M Santosham. (1999). A case-control study of risk factors for Haemophilus influenzae type B disease in Navajo children.. American Journal of Tropical Medicine and Hygiene. 60(2). 263–266. 7 indexed citations

19.

Thyrault, Martial, Bertrand Gachot, & Mark Wolff. (1993). CHOLECYSTITE AIGUE ALITHIASIQUE A SALMONELLA ENTERITIDIS AU COURS DU SIDA. La Presse Médicale. 22(16). 785–785. 2 indexed citations

20.

Santosham, M, G. William Letson, Mark Wolff, et al.. (1991). A Field Study of the Safety and Efficacy of Two Candidate Rotavirus Vaccines in a Native American Population. The Journal of Infectious Diseases. 163(3). 483–487. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact